New variant of SARS-CoV-2 in UK causes surge of COVID-19

Kirby, Tony

doi:10.1016/s2213-2600(21)00005-9

Cited by 330 publications

(286 citation statements)

References 0 publications

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…The rapid surge inSARS-CoV-2 cases due to the Variant of Concern (VOC) 202012/01, also known as lineage B.1.1.7 or 20B/501Y.V1, in the United Kingdom (UK) 1 raised concerns in several countries. Many of these countries had direct flights to and from UK and the variant was associated with high transmissibility.…”

Section: Main Textmentioning

confidence: 99%

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

Sapkal

Yadav

Ella

et al. 2021

Preprint

View full text Add to dashboard Cite

We performed the plaque reduction neutralization test (PRNT50) using sera collected from the recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.

show abstract

Section: Main Textmentioning

confidence: 99%

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

Sapkal

Yadav

Ella

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…While a recent study has provided an improved version of CRISPR Diagnostics, which bypasses the amplification step (Fozouni et al, 2020), more optimization is needed to provide a fully instrument-free diagnostic platform. Importantly, CRISPR Diagnostics has the provision to detect single nucleotide mismatches and hence will serve as a rapid diagnostic tool to detect any new mutations arising in the SARS-CoV-2 genome (Kirby, 2021). Some of these mutations have already been shown spreading at a higher rate and thus it is imperative to adopt and deploy CRISPR-based diagnostics to extensively screen the transmission of these new SARS-CoV-2 strains.…”

Section: Discussionmentioning

confidence: 99%

A Saliva-Based RNA Extraction-Free Workflow Integrated With Cas13a for SARS-CoV-2 Detection

Azmi

Faizan

Kumar

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

A major bottleneck in scaling-up COVID-19 testing is the need for sophisticated instruments and well-trained healthcare professionals, which are already overwhelmed due to the pandemic. Moreover, the high-sensitive SARS-CoV-2 diagnostics are contingent on an RNA extraction step, which, in turn, is restricted by constraints in the supply chain. Here, we present CASSPIT (Cas13 Assisted Saliva-based & Smartphone Integrated Testing), which will allow direct use of saliva samples without the need for an extra RNA extraction step for SARS-CoV-2 detection. CASSPIT utilizes CRISPR-Cas13a based SARS-CoV-2 RNA detection, and lateral-flow assay (LFA) readout of the test results. The sample preparation workflow includes an optimized chemical treatment and heat inactivation method, which, when applied to COVID-19 clinical samples, showed a 97% positive agreement with the RNA extraction method. With CASSPIT, LFA based visual limit of detection (LoD) for a given SARS-CoV-2 RNA spiked into the saliva samples was ~200 copies; image analysis-based quantification further improved the analytical sensitivity to ~100 copies. Upon validation of clinical sensitivity on RNA extraction-free saliva samples (n = 76), a 98% agreement between the lateral-flow readout and RT-qPCR data was found (Ct<35). To enable user-friendly test results with provision for data storage and online consultation, we subsequently integrated lateral-flow strips with a smartphone application. We believe CASSPIT will eliminate our reliance on RT-qPCR by providing comparable sensitivity and will be a step toward establishing nucleic acid-based point-of-care (POC) testing for COVID-19.

show abstract

“…8,9 The initial workup on this strain showed that it is a result of antigenic drift with 17 accumulated mutations and is seventy percent more transmissible than the already circulating original form of the virus. 11,12 Out of these 17 mutations, eight are on the spike protein: the portion of the coronavirus's shell that allows this virus to bind to receptors on host cell surfaces and thus infecting these cells. 11 The first detection of the mutation from the UK could be attributed to its strong viral surveillance program wherein the country tries to analyze genetic sequences of ten percent of all new cases and compare them to spot any changes.…”

mentioning

confidence: 99%

“…the requirement of hospital admissions, disease severity, or mortality. 12 The new strain is also vaccine susceptible and is does not have the vaccine escape capability. 13 Furthermore, there are some unconfirmed reports based on preliminary evidence suggestive of higher mortality with the new variant.…”

mentioning

confidence: 99%

“…9 Anyways, the increased infectiousness of the new variant of the SARS-CoV-2 will result in a higher number of COVID-19 cases, and thus when it was expected that a plummet in case-load may occur due to the vaccines against this virus, a surge in cases might be seen which would ultimately overwhelm the healthcare systems around the world. 12 Also, there are reports from South Africa which is currently facing a second surge of COVID-19 cases, due to a new variant of SARS-CoV-2 known as, B.1.351. 9 This variant has been known to evade the body's immune response and is detected in samples as early as October 2020.…”

mentioning

confidence: 99%

See 1 more Smart Citation